



# DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

**Date:** December 16, 2021

**Time:** 10:00am – 3:00pm (CST)

**Location:** 221 Metro Dr,  
Jefferson City, MO 65109 / Webex  
**See Additional Details Below**

### December 16, 2021 DPAC Meeting Additional Details

The December 16<sup>th</sup> DPAC meeting will have both in-person and virtual attendance options. The meeting will be hosted at the Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room located at 221 Metro Dr, Jefferson City, MO 65109. Please enter and exit through the lower level only. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961** and review the Meeting Safety Guidelines prior to the meeting (guidelines are listed at the end of this agenda).

[Join Webex Meeting](#)

Meeting number (access code): 1779 94 4944  
Meeting password: QBmXwRJR487

**Join from a Video System/Application**  
Dial [1779944944@stateofmo.webex.com](tel:1779944944)  
Or dial 173.243.2.68 and enter the meeting number

**Join from a Mobile Device (attendees only)**  
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

### Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

### Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

### New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	

### Opioid Policy Review

11:00 – 11:45	<u>Opioid-Related Edits for Review</u>	Josh Moore
	i. High Risk Therapies Clinical Edit	
	ii. Morphine Milligram Equivalent (MME) Accumulation Clinical Edit	
	iii. Opioid Dependence Agents PDL Edit	
	iv. Opioid Emergency Reversal Agents PDL Edit	

- v. Opioids, Long Acting PDL Edit
- vi. Opioids, Short Acting Clinical Edit
- vii. Tramadol-Like Agents PDL Edit
- viii. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit

### Clinical and Fiscal Edit Review

11:45 – 12:45

#### Existing Criteria

Josh Moore

- i. 15 Day Supply Oral Oncology Fiscal Edit
- ii. Butalbital Combinations without Codeine Clinical Edit
- iii. Butalbital Combinations Excessive Therapy Edit
- iv. Diabetic Supply Quantity Limit Fiscal Edit
- v. Out-of-State, Non-Bordering Pharmacies Fiscal Edit
- vi. Selzentry Clinical Edit

#### New Criteria or Revision of Existing Criteria

- i. 15 Day Supply Fiscal Edit
- ii. Acetaminophen Cumulative Dose Clinical Edit
- iii. Antipsychotics, 1<sup>st</sup> Generation (Typical) Clinical Edit
- iv. Antipsychotics, 2<sup>nd</sup> Generation (Atypical) Clinical Edit
- v. Benzodiazepine, Select Oral Clinical Edit
- vi. BiDil Clinical Edit
- vii. Biosimilar vs. Reference Products Fiscal Edit
- viii. Corlanor Clinical Edit
- ix. Empaveli Clinical Edit
- x. Extended Supply Fiscal Edit
- xi. High Cost Medications Fiscal Edit
- xii. Kerendia Clinical Edit
- xiii. Non-Oral Contraceptives Fiscal Edit
- xiv. Pompe Disease Clinical Edit
- xv. Spinal Muscular Atrophy (SMA) Clinical Edit

### Break

12:45 – 1:00

Lunch

### Preferred Drug List Edit Review

1:00 – 2:00

#### Existing Criteria

Josh Moore

- i. Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists
- ii. Anticonvulsants, Dravet Syndrome
- iii. Antiemetics, THC Derivatives
- iv. Anti-Parkinsonism, MAO-B Inhibitors
- v. Anti-Parkinsonism, Non-Ergot Dopamine Agonists
- vi. GI Motility Agents, Chronic
- vii. Sedative Hypnotics
- viii. Somatostatin Analogs

#### New Criteria or Revision of Existing Criteria

- i. Antiandrogenic Agents
- ii. Antiemetics, 5-HT<sub>3</sub> and NK<sub>1</sub> Injectables
- iii. Antiemetics, 5-HT<sub>3</sub>, NK<sub>1</sub> and Other Select Non-Injectables
- iv. Anti-Migraine, Alternative Oral Agents
- v. Anti-Migraine, Serotonin (5-HT<sub>1</sub>) Receptor Agonists
- vi. Antiretroviral Therapy (ART)

- vii. Bile Salt Agents
- viii. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- ix. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors
- x. Fibromyalgia Agents
- xi. Glucagon Agents
- xii. Hereditary Angioedema Agents
- xiii. Homozygous Familial Hypercholesterolemia (HoFH)
- xiv. Neuropathic Pain Agents
- xv. NSAIDs
- xvi. Skeletal Muscle Relaxants
- xvii. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors

**Program Utilization Information – Conduent Update**

2:00 – 2:30

Reports

Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

**Other Business/Closing Comments**

2:30 – 2:50

Other Business

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.*

<b>Next Meeting: March 17, 2022</b>	
<u>Meeting location and attendance options subject to change</u>	
Lower Level CEO Room Missouri Coalition for Community Behavioral Healthcare 221 Metro Drive Jefferson City, MO 65109 <i>Public attendance may be limited</i>	Webex

## Meeting Safety Guidelines

As we transition back to offering more in-person meeting opportunities, the following guidelines should be followed for all trainings and meetings we host in our building.



### Before the meeting.

- All attendees should stay home if feeling unwell or have a fever, cough, respiratory symptoms, or have tested positive for COVID-19 within the past 14 days.
- There will be a sign in sheet with COVID-19 screening questions for all attendees to fill out before the meeting begins.
- Please use a mask, hand sanitizer, tissue, and other hygiene products available in the meeting room.
- The capacity for the meeting space will be limited for in person attendance to allow for adequate social distancing.



### During the meeting.

- Enter the building through the lower back entrance to the meeting rooms.
- We recommend wearing a mask during the meeting if adequate social distancing is not possible. There will be masks available in the meeting room.
- Use proper hand hygiene and respiratory etiquette. There will be hand sanitizer and sinks to wash hands, as needed.
- Maintain social distance and avoid crowding the lobby and restroom areas.
- The water fountain will not be available for use, but there is a water cooler available to fill cups.
- If lunch is provided, it may be prepackaged, or staff will provide food service.
- Open the doors to the conference rooms to help with air circulation.

**Motion to Close:** *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*